Ergomed appoints Dr Jan Petracek as CEO of subsidiary PrimeVigilance

AIM-listed Ergomed, a provider of services to the pharmaceutical sector, has appointed Dr Jan Petracek as chief executive of its drug safety subsidiary Prime Vigilance.

He will succeed Neil Clark who is leaving the company on 16 April to become chief executive of Destiny Pharma, a novel antimicrobials company.

Clark will remain on the PrimVigilance’s board as a non-executive director and as a consultant during a transition period.

Petracek, who is the former head of risk management at the European Medicines Agency (EMA), joined Ergomed last November as chief executive of European PharmInvent Services following its acquisition and integration into PrimeVigilance.

Ergomed chief executive Dr Miroslav Reljanovic said: "I would like to give my sincere thanks to Neil for his eight years' service to Ergomed. He has helped the company transition from a private company through the IPO process in 2014 and latterly, overseen a period of strong growth in PrimeVigilance.

"We are fortunate to have in the wings a replacement CEO of the calibre of D. Jan Petracek. As founder of PharmInvent and former regulator at EMA, his unique combination of entrepreneurship and specialist pharmacovigilance expertise will serve to drive forward our pharmacoviglance businesses."

Shares in Ergomed up 1.74% to 205p at 0900 BST.